Presentation is loading. Please wait.

Presentation is loading. Please wait.

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,

Published byNikolas Reuter Modified over 6 years ago

Similar presentations

Presentation on theme: "Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,"— Presentation transcript:

1 Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz, R. Schille, A.C. Rodloff  Clinical Microbiology and Infection  Volume 9, Issue 5, Pages (May 2003) DOI: /j x Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

2 Figure 1 Antibiotics and combinations of antibiotics used in 83 episodes of i.v. therapy. Clinical Microbiology and Infection 2003 9, DOI: ( /j x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

3 Figure 2 MICs of ceftazidime and moxifloxacin against Pseudomonas aeruginosa clones with 38 PFGE-patterns at the beginning of the investigation (t = 0; 38 isolates), after 1 year (t = 1 year; 31 isolates) and after 2 years (t = 2 years; 19 isolates). Clinical Microbiology and Infection 2003 9, DOI: ( /j x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

4 Figure 3 MICs of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa clones with 38 PFGE patterns at the beginning of the investigation (t = 0; 38 isolates), after 1 year (t = 1 year; 31 isolates) and after 2 years (t = 2 years; 19 isolates). Clinical Microbiology and Infection 2003 9, DOI: ( /j x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

5 Figure 4 MICs of gentamicin and tobramycin against Pseudomonas aeruginosa clones with 38 PFGE patterns at the beginning of the investigation (t = 0; 38 isolates), after 1 year (t = 1 year; 31 isolates) and after 2 years (t = 2 years; 19 isolates). Clinical Microbiology and Infection 2003 9, DOI: ( /j x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

6 Figure 5 MICs of meropenem and imipenem against Pseudomonas aeruginosa clones with 38 PFGE patterns at the beginning of the investigation (t = 0; 38 isolates), after 1 year (t = 1 year; 31 isolates) and after 2 years (t = 2 years; 19 isolates). Clinical Microbiology and Infection 2003 9, DOI: ( /j x) Copyright © 2003 European Society of Clinical Infectious Diseases Terms and Conditions

Download ppt "Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times  F.B. Spencker, L. Staber, T. Lietz,"

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages 19-23.

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Laboratory diagnosis and biosafety issues of biological warfare agents

Laboratory diagnosis and biosafety issues of biological warfare agents
Metallo-β-lactamase-producing Pseudomonas aeruginosa in the Netherlands: the nationwide emergence of a single sequence type  A.K. Van der Bij, D. Van.

Metallo-β-lactamase-producing Pseudomonas aeruginosa in the Netherlands: the nationwide emergence of a single sequence type  A.K. Van der Bij, D. Van.
Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time.

Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time.
Interpretive criteria of ceftibuten disk diffusion susceptibility tests according to the DIN 58 940 method  Kleinkauf N. , Rodloff A.C.   Clinical Microbiology.

Interpretive criteria of ceftibuten disk diffusion susceptibility tests according to the DIN method  Kleinkauf N. , Rodloff A.C.   Clinical Microbiology.
Frequency and molecular diversity of Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study  Dominique S.

Frequency and molecular diversity of Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study  Dominique S.
Typing of Pseudomonas aeruginosa strains from patients with cystic fibrosis: phenotyping versus genotyping  Nicole Renders, Alex van Belkum, Alfonso Barth,

Typing of Pseudomonas aeruginosa strains from patients with cystic fibrosis: phenotyping versus genotyping  Nicole Renders, Alex van Belkum, Alfonso Barth,
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients  R. Cantón, N. Cobos,

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients  R. Cantón, N. Cobos,
Approach to diagnosis of infective endocarditis

Approach to diagnosis of infective endocarditis
Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-β- lactamase-producing clone with a heterogeneous carbapenem resistance.

Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-β- lactamase-producing clone with a heterogeneous carbapenem resistance.
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria  M.J. Rybak  Clinical Microbiology and Infection 
Herpes zoster in non-hospitalized children

Herpes zoster in non-hospitalized children
Pseudomonas aeruginosa diversity in distinct paediatric patient groups

Pseudomonas aeruginosa diversity in distinct paediatric patient groups
Quinolone resistance among Shigella spp

Quinolone resistance among Shigella spp
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics 

Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics 
Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time.

Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time.
Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan  P.R. Hsueh, S.P. Tseng, L.J. Teng, S.W. Ho 

Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan  P.R. Hsueh, S.P. Tseng, L.J. Teng, S.W. Ho 
C.G. Giske, C. Borén, B. Wretlind, G. Kronvall 

C.G. Giske, C. Borén, B. Wretlind, G. Kronvall 
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.

Similar presentations

Ads by Google